Mini Review
Volume 6:5, 2023

Journal of Biomedical and Pharmaceutical Sciences

ISSN: 2952-8100 Open Access

Alterations in Eosinophil Cationic Protein in Asthma and CRSwNP Participants Receiving Dupilumab

Matsumoto Yasushi*

Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan

Abstract

Asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) are chronic inflammatory diseases that affect the respiratory and nasal passages, respectively. Both conditions are often characterized by elevated levels of eosinophil, a type of white blood cell that plays a crucial role in the immune response. Eosinophilic inflammation is a key feature of these diseases and is associated with a range of symptoms and complications. Dupilumab is a monoclonal antibody that targets the interleukin-4 receptor alpha subunit, inhibiting the signaling of both interleukin-4 (IL-4) and interleukin-13 (IL-13). Dupilumab has demonstrated remarkable efficacy in treating asthma and CRSwNP, significantly reducing symptoms and improving the quality of life for many patients. This success can be attributed to its ability to reduce eosinophilic inflammation, which leads to alterations in various biomarkers, including Eosinophil Cationic Protein (ECP).

Keywords: Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) • Dupilumab • Eosinophilic inflammation • Eosinophil Cationic Protein (ECP)

Introduction

Eosinophil cationic protein is a biomarker that is secreted by eosinophil and has long been associated with eosinophilic inflammation. This protein can cause tissue damage and has been implicated in the pathogenesis of asthma and CRSwNP. In this review, we will explore the alterations in ECP levels and their significance in individuals with asthma and CRSwNP who receive Dupilumab as part of their treatment regimen. Asthma and CRSwNP are characterized by chronic inflammation in the airways and nasal passages, respectively. Eosinophil is a type of white blood cell that plays a central role in allergic and eosinophilic inflammation. These cells release a variety of pro-inflammatory mediators, including Eosinophil Cationic Protein (ECP), during an immune response. ECP is a cytotoxic protein that can damage the epithelial lining of the airways and nasal passages, contributing to the pathogenesis of these conditions. Eosinophilic inflammation in asthma is associated with increased airway hyper responsiveness, bronchoconstriction, mucus production, and remodelling of the airway walls. In CRSwNP, eosinophil infiltrates the nasal polyps and contributes to nasal congestion, loss of smell, and exacerbation of symptoms. Therefore, the reduction of eosinophilic inflammation is a primary target in the management of both conditions.

Literature Review

Dupilumab represents a significant advancement in the treatment of asthma and CRSwNP. By targeting the interleukin-4 receptor alpha subunit, it inhibits the signaling of both IL-4 and IL-13, which are key drivers of eosinophilic inflammation. Dupilumab reduces inflammation, improves lung function in asthma, and decreases nasal polyp size in CRSwNP patients. The clinical efficacy of Dupilumab in asthma and CRSwNP is well-established, with numerous studies demonstrating its ability to reduce symptoms and improve patients' quality of life. Its mechanism of action involves not only a reduction in eosinophilic inflammation but also an alteration in the levels of eosinophilic biomarkers, such as ECP [1].

One of the primary effects of Dupilumab treatment in individuals with asthma and CRSwNP is the significant reduction in ECP levels. This decrease in ECP is directly related to the suppression of eosinophilic inflammation due to the inhibition of IL-4 and IL-13 signaling. Studies have consistently shown that Dupilumab can lead to a substantial reduction in ECP levels in both asthmatic and CRSwNP patients. The reduction in ECP levels with Dupilumab treatment has several important clinical implications. First, it correlates with improved symptoms and quality of life in patients. Reduced ECP levels are associated with a decrease in airway hyper responsiveness, bronchoconstriction, and nasal congestion. As a result, patients experience better control of their disease and a reduction in exacerbations.

Furthermore, the reduction in ECP levels reflects the decreased potential for tissue damage. ECP can cause epithelial damage in the airways and nasal passages, leading to tissue remodelling and fibrosis. By lowering ECP levels, Dupilumab helps prevent or reverse this damage, preserving respiratory and nasal function. The alteration of ECP levels can also serve as a valuable biomarker for monitoring disease activity and treatment response. Clinicians can measure ECP levels to assess the effectiveness of Dupilumab therapy and adjust treatment plans accordingly [2]. This biomarker helps in identifying patients who may benefit most from Dupilumab and those who might require alternative therapies.

While the alterations in ECP levels with Dupilumab treatment have proven to be beneficial for many asthma and CRSwNP patients, some challenges and considerations need to be addressed. Not all patients respond equally to Dupilumab treatment. While some individuals experience a dramatic reduction in ECP levels and symptom improvement, others may show a more modest response. Variability in treatment response may be influenced by individual factors, including genetics, disease severity, and comorbidities.

The long-term effects of Dupilumab treatment on ECP levels and overall health require further investigation. It is essential to determine whether sustained ECP reduction leads to a decrease in disease progression and complications over time. Additionally, the safety of long-term Dupilumab use needs to be closely monitored. In some cases, Dupilumab may be used in combination with other treatments, such as corticosteroids or biologics targeting different pathways. The interactions between Dupilumab and these treatments and their impact on ECP levels need to be studied to optimize therapeutic approaches [3].

***Address for Correspondence:** Matsumoto Yasushi, Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan, E-mail: yasushi@matsum.ac.jp*

Received: 04 September, 2023, Manuscript No. jbps-23-116707; **Editor Assigned:** 06 September, 2023, PreQC No. P-116707; **Reviewed:** 18 September, 2023, QC No. Q-116707; **Revised:** 23 September, 2023, Manuscript No. R-116707; **Published:** 30 September, 2023, DOI: 10.37421/2952-8100.2023.6.438

Discussion

The treatment landscape for chronic respiratory conditions, such as asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), has seen remarkable advancements in recent years. Dupilumab, a monoclonal antibody targeting the interleukin-4 receptor alpha subunit, has emerged as a breakthrough therapy for these conditions, significantly improving symptoms and quality of life for many patients. Central to its mechanism of action is the reduction of eosinophilic inflammation, and a key biomarker reflecting this process is Eosinophil Cationic Protein (ECP) [4]. This discussion delves into the implications of alterations in ECP levels in asthma and CRSwNP patients receiving Dupilumab, highlighting the clinical relevance, challenges, and avenues for further research.

The primary clinical implication of ECP reduction in patients undergoing Dupilumab treatment is the substantial improvement in disease control. In both asthma and CRSwNP, eosinophilic inflammation plays a pivotal role in symptom severity. By effectively suppressing this inflammation, Dupilumab leads to a marked reduction in ECP levels, which in turn is correlated with improved lung function in asthma and reduced nasal polyp size in CRSwNP. This has a direct impact on the patient's quality of life, as they experience fewer exacerbations, better symptom control, and enhanced overall well-being. Moreover, the decrease in ECP levels suggests that Dupilumab therapy can prevent or reverse tissue damage, which is particularly relevant in chronic conditions like asthma and CRSwNP. ECP is cytotoxic and can cause epithelial damage in the airways and nasal passages, leading to structural remodelling and fibrosis. By lowering ECP levels, Dupilumab has the potential to preserve respiratory and nasal function and halt disease progression [5].

The alteration of ECP levels has the potential to serve as a valuable biomarker for monitoring disease activity and evaluating treatment response. Clinicians can measure ECP levels to assess the effectiveness of Dupilumab therapy, enabling them to tailor treatment plans for individual patients. This personalized approach ensures that patients receive the most suitable and effective treatment, minimizing the risk of overmedication or under treatment. ECP levels can also assist in identifying patients who are most likely to benefit from Dupilumab, making it an invaluable tool for stratifying patients based on their response to treatment. For individuals with robust ECP reduction, Dupilumab is particularly effective, and this biomarker allows clinicians to identify these patients early in their treatment journey.

While the alteration in ECP levels with Dupilumab treatment is promising, several challenges and considerations must be addressed. Not all patients respond equally to Dupilumab treatment. There is significant variability in the degree of ECP reduction and symptom improvement among individuals. This variation can be attributed to factors such as genetics, disease severity, and the presence of comorbidities. Understanding the factors that influence treatment response is crucial for tailoring therapy to the specific needs of each patient. The long-term effects of Dupilumab treatment on ECP levels and overall health remain an area of active research. While initial results are promising, more extensive and longer-term studies are needed to determine whether sustained ECP reduction with Dupilumab can prevent or slow disease progression and reduce the risk of complications. Furthermore, the safety of prolonged Dupilumab use needs to be closely monitored.

In some cases, Dupilumab is used in combination with other treatments, such as corticosteroids or other biologics targeting different inflammatory pathways. The interactions between Dupilumab and these treatments and their impact on ECP levels require further investigation. Optimizing combination therapies can enhance the overall treatment strategy for patients with severe or refractory disease. Longitudinal studies are needed to assess the long-term safety and efficacy of Dupilumab, especially in patients with severe and refractory disease. Tracking ECP levels and correlating them with disease progression over extended periods will provide critical insights into the treatment's potential to modify the natural course of these conditions. Research on the interactions between Dupilumab and other treatments, including their combined effect on ECP levels, is essential [6].

Conclusion

Dupilumab has revolutionized the treatment of asthma and CRSwNP by effectively targeting eosinophilic inflammation. One of the notable alterations associated with Dupilumab treatment is the reduction in Eosinophil Cationic Protein (ECP) levels. This decrease in ECP is closely linked to improved symptom control and a higher quality of life for patients. The alterations in ECP levels serve as a valuable biomarker for monitoring disease activity, allowing clinicians to assess treatment efficacy and make informed decisions about patient care. However, some challenges remain, such as variability in treatment response and the long-term effects of Dupilumab therapy. Further research is needed to address these issues and refine the use of Dupilumab in the management of asthma and CRSwNP. In conclusion, the alteration in ECP levels with Dupilumab treatment represents a promising avenue in the management of these chronic inflammatory conditions. With ongoing research and a deeper understanding of the mechanisms at play, we can continue to improve the lives of asthma and CRSwNP patients by harnessing the potential of this ground-breaking therapy.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Bachert, Claus, Joseph K. Han, Martin Desrosiers and Peter W. Hellings, et al. “Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.” *Lancet* 394 (2019): 1638–1650.
2. Pelaia, Corrado, Giulia Pelaia, Claudia Crimi and Angelantonio Maglio, et al. “Biological therapy of severe asthma with dupilumab, a dual receptor antagonist of interleukins 4 and 13.” *Vaccines* 10 (2022): 974.
3. Acharya, K. Ravi and Steven J. Ackerman. “Eosinophil granule proteins: Form and function.” *J Biol Chem* 289 (2014): 17406–17415.
4. Reddel, Helen K., Leonard B. Bacharier, Eric D. Bateman and Christopher E. Brightling, et al. “Global initiative for asthma strategy 2021: Executive summary and rationale for key changes.” *Am J Respir Crit Care Med* 205 (2022): 17–35.
5. Louis, Renaud, Imran Satia, Inigo Ojanguren and Florence Schleich, et al. “European Respiratory Society guidelines for the diagnosis of asthma in adults.” *Eur Respir J* 60 (2022): 2101585.
6. Franceschi, Elisa, Nora Drick, Jan Fuge and Tobias Welte, et al. “Eosinophilic cationic protein as marker for response to antibody therapy in severe asthma.” *ERJ Open Res* 8 (2022).

How to cite this article: Yasushi, Matsumoto. “Alterations in Eosinophil Cationic Protein in Asthma and CRSwNP Participants Receiving Dupilumab.” *J Biomed Pharma Sci* 6 (2023): 438.